Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/188930
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Marín Jiménez, Juan A. | - |
dc.contributor.author | Oliva, Marc | - |
dc.contributor.author | Peinado Martín, Paloma | - |
dc.contributor.author | Cabezas Camarero, Santiago | - |
dc.contributor.author | Plana Serrahima, Maria | - |
dc.contributor.author | Vázquez Masedo, Gonzalo | - |
dc.contributor.author | Lozano Borbalas, Alicia | - |
dc.contributor.author | Cabrera Martín, María N. | - |
dc.contributor.author | Esteve, Anna | - |
dc.contributor.author | Iglesias Moreno, María C. | - |
dc.contributor.author | Vilajosana Altamis, Esther | - |
dc.contributor.author | Arribas Hortigüela, Lorena | - |
dc.contributor.author | Taberna, Miren | - |
dc.contributor.author | Pérez Segura, Pedro | - |
dc.contributor.author | Mesía Nin, Ricard | - |
dc.date.accessioned | 2022-09-12T10:55:10Z | - |
dc.date.available | 2022-09-12T10:55:10Z | - |
dc.date.issued | 2022-07-22 | - |
dc.identifier.issn | 2234943X | - |
dc.identifier.uri | http://hdl.handle.net/2445/188930 | - |
dc.description.abstract | Objectives Induction chemotherapy (ICT) followed by definitive treatment is an accepted non-surgical approach for locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, ICT remains a challenge for cisplatin-unfit patients. We evaluated paclitaxel and cetuximab (P-C) as ICT in a cohort of LA-HNSCC patients unfit for cisplatin. Materials and MethodsThis is a retrospective analysis of patients with newly diagnosed LA-HNSCC considered unfit for cisplatin-based chemotherapy (age >70 and/or ECOG >= 2 and/or comorbidities) treated with weekly P-C followed by definitive radiotherapy and cetuximab (RT-C) between 2010 and 2017. Toxicity and objective response rate (ORR) to ICT and RT-C were collected. Median overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Cox regression analysis was performed to determine baseline predictors of OS and PFS. ResultsA total of 57 patients were included. Grade 3-4 toxicity rate to ICT was 54.4%, and there was a death deemed treatment-related (G5). P-C achieved an ORR of 66.7%, including 12.3% of complete responses (CR). After P-C, 45 patients (78.9%) continued with concomitant RT-C. Twenty-six patients (45.6%) achieved a CR after definitive treatment. With a median follow-up of 21.7 months (range 1.2-94.6), median OS and PFS were 22.9 months and 10.7 months, respectively. The estimated 2-year OS and PFS rates were 48.9% and 33.7%, respectively. Disease stage had a negative impact on OS (stage IVb vs. III-IVa: HR = 2.55 [1.08-6.04], p = 0.03), with a trend towards worse PFS (HR = 1.92 [0.91-4.05], p = 0.09). Primary tumor in the larynx was associated with improved PFS but not OS (HR = 0.45 [0.22-0.92], p = 0.03, and HR = 0.69 [0.32-1.54], p = 0.37, respectively). ConclusionP-C was a well-tolerated and active ICT regimen in this cohort of LA-HNSCC patients unfit for cisplatin-based chemotherapy. P-C might represent a valid ICT option for unfit patients and may aid patient selection for definitive treatment. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media SA | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2022.953020 | - |
dc.relation.ispartof | Frontiers in Oncology, 2022, vol. 12, num. 953020 | - |
dc.relation.uri | https://doi.org/10.3389/fonc.2022.953020 | - |
dc.rights | cc by (c) Marín Jiménez, Juan A. et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer de cap | - |
dc.subject.classification | Càncer de coll | - |
dc.subject.classification | Quimioteràpia del càncer | - |
dc.subject.classification | Radioteràpia | - |
dc.subject.other | Head cancer | - |
dc.subject.other | Neck cancer | - |
dc.subject.other | Cancer chemotherapy | - |
dc.subject.other | Radiotherapy | - |
dc.title | Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-08-18T11:34:27Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35936723 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fonc-12-953020.pdf | 2.39 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License